Protara Therapeutics
TARA
30 hedge funds and large institutions have $13.6M invested in Protara Therapeutics in 2017 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
20% more funds holding
Funds holding: 25 → 30 (+5)
0.01% more ownership
Funds ownership: 1.25% → 1.26% (+0.01%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
22% less capital invested
Capital invested by funds: $17.5M → $13.6M (-$3.88M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
+$77.5K |
| 2 |
Renaissance Technologies
New York
|
+$59.3K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$39.5K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$31K |
| 5 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
+$18.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
-$27.4K |
| 2 |
VF
Virtu Financial
New York
|
-$23K |
| 3 |
WS
Wedbush Securities
Los Angeles,
California
|
-$14.8K |
| 4 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$8.02K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$4.49K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
BlackRock
New York
| $10K | +$481 | +6 | +5% |
|
|
PCM
27
Prelude Capital Management
New York
| $9K | +$9.94K | +124 | New |
|
28
Royal Bank of Canada
Toronto,
Ontario, Canada
| $7K | +$962 | +12 | +14% |
|
29
Macquarie Group
Sydney, NSW 2000,
Australia
| $6K | +$6.82K | +85 | New |
|
|
PI
30
Pharmstandard International
Luxembourg
| $3.17K | – | – | – |
|
|
VF
31
Virtu Financial
New York
| – | -$23K | -293 | Closed |
|
TARA Hedge Fund Activity: Q4 2017 in Review
30 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q4 2017, worth a combined $13.6M — down 22% from $17.5M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new TARA positions and 1 closed out — a net gain of 5 holders — while 6 added to existing stakes and 6 trimmed.
The largest buyer was DRW Securities, opening a new position worth an estimated $77.5K. The largest seller was Kornitzer Capital Management, cutting an estimated $27.4K.
- 30 institutional investors held Protara Therapeutics (TARA) as of Q4 2017, up from 25 in Q3 2017.
- Funds reported $13.6M of Protara Therapeutics stock for Q4 2017, down 22% quarter-over-quarter.
- 6 funds opened new Protara Therapeutics positions in Q4 2017 and 1 closed out, a net change of +5 holders.
- The largest Protara Therapeutics buyer in Q4 2017 was DRW Securities, an estimated $77.5K added.
- The largest Protara Therapeutics seller in Q4 2017 was Kornitzer Capital Management, an estimated $27.4K sold.
Based on aggregated 13F filings for Q4 2017.